An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Rate of pathological complete response
Event driven
No
Clinical Trials
Study Director
Hoffmann-La Roche
France: Agence francaise de securite sanitaire des produits de sante (AFSSAPS)
ML21531
NCT00717405
October 2008
September 2014
Name | Location |
---|